GPCR

GPCR Therapeutics is a South Korean clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting G protein-coupled receptor (GPCR) heteromers. Its lead asset, Burixafor (GPC-100), is a CXCR4 inhibitor being advanced for oncology indications, as CXCR4 is overexpressed in more than 23 cancer types. The company's proprietary drug discovery platform leverages GPCR heteromer biology to identify and validate targets with greater selectivity and reduced side-effect profiles than conventional GPCR drug approaches. GPCR Therapeutics serves as a specialized oncology-focused biotech working to translate heterodimer science into clinical therapies.